Targets of protective tumor immunity

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 74-80

  Dranoff, Glenn ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CTLA 4; ERp5; GM CSF; MICA; Myeloma; NKG2D

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELAN A; MELANOMA VACCINE; NATURAL KILLER CELL RECEPTOR NKG2D; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; CANCER VACCINE; CD11B ANTIGEN; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; ITGAM PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PDIA6 PROTEIN, HUMAN; PROTEIN DISULFIDE ISOMERASE; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CELL THERAPY; CONFERENCE PAPER; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; MELANOMA; NONHUMAN; TUMOR IMMUNITY; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; GENETICS; IMMUNITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; REVIEW;

ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MELANOMA; NEOPLASMS; PROTEIN DISULFIDE-ISOMERASES;

EID: 70350504578     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04938.x     Document Type: Conference Paper

References (44)

1. Dranoff, G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4: 11-22.
2. Clark, W. et al. 1969. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29: 705-726.
3. Oble, D.A. et al. 2009. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 9: 3.
4. Scanlan, M.J. et al. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188: 22-32.
5. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11: 263-270.
6. Boon, T. et al. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
7. Dunn, G.P., L.J. Old & R.D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
8. Rabinovich, G.A., D. Gabrilovich & E.M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
9. Steinman, R.M. & I. Mellman. 2004. Immunotherapy: bewitched, bothered, and bewildered no more. Science 305: 197-200.
10. Gilboa, E. 2007. DC-based cancer vaccines. J. Clin. Invest. 117: 1195-1203.
11. Dougan, M. & G. Dranoff. 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27: 83-117.
12. Chambers, C.A. et al. 2001. CTLA-4-mediatedinhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19: 565-594.
13. Salomon, B. & J.A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252. (Pubitemid 32368035)
14. Wing, K. et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275.
15. Tivol, E.A. et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
16. Leach, D.R., M.F. Krummel & J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
17. van Elsas, A., A. Hurwitz & J Allison. 1999. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, J. Exp. Med. 190: 355-366.
18. van Elsas, A. et al. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194: 481-189.
19. Quezada, S.A. et al. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Can. Invest. 116: 1935-1945.
20. Dranoff, G. et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Svi. USA 90: 3539-3543. (Pubitemid 23111402)
21. Jinushi, M., ES. Hodi & G. Dranoff. 2008. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222: 287-298.
22. Soiffer, R. et al. 1998. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95: 13141-13146. (Pubitemid 28509538)
23. Soiffer, R. et al. 2003. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma, J. Clin. Oncol. 21: 3343-3350. (Pubitemid 46606268)
24. Hodi, F.S. et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100:4712-4717.
25. Hodi, F.S. et al. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105: 3005-3010.
26. Attia, P. et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Can. Oncol. 23: 6043-6053.
27. Hodi, ES. & G. Dranoff. 2006. Combinatorial cancer immunotherapy. Adv. Immunol. 90: 337-360.
28. Jinushi, M., F.S. Hodi & G. Dranoff. 2006. Therapyinduced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 103: 9190-9195. (Pubitemid 43902554)
29. Groh, V. et al. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279: 1737-1740.
30. Ogasawara, K. & L.L. Lanier. 2005. NKG2D in NK and T cell-mediated immunity. J. Clin. Immunol. 25: 534-540.
31. Smyth, M.J. et al. 2005. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202: 583-588.
32. Guerra, N. et al. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
33. Groh, V. et al. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450. (Pubitemid 26367163)
34. Gasser, S. et al. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. (Pubitemid 41232299)
35. Groh, V. et al. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738. (Pubitemid 35177960)
36. Salih, H.R., H.G. Rammensee & A. Steinle. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169: 4098-4102.
37. Doubrovina, E.S. et al. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171: 6891-6899.
38. Groh, V. et al. 2005. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. USA 102: 6461-6466. (Pubitemid 40617465)
39. Fonseca, C. et al. 2009. Protein disulfide isomerases are antibody targets during immune-mediated tumordestruction. Blood 113: 1681-1688.
40. Ellgaard, L. & L.W. Ruddock. 2005. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 6: 28-32. (Pubitemid 41710070)
41. Kaiser, B.K. et al. 2007. Disulphide-isomeraseenabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
42. Waldhauer, I. et al. 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68: 6368-6376.
43. Jinushi, M. et al. 2008. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. USA 105: 1285-1290.
44. Kuehl, W.M. & P.L. Bergsagel. 2002. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2: 175-187.